Integrating the values of molecular descriptors in the prediction of biopharmaceutical properties for new compounds with dibenzothiepine structure

Farmacia

Volumn 59, Issue 6, 2011, Pages 820-829

  Stecoza, Camela Elena ^a,c   Rǎdulescu, Flavian Ştefan ^a,c   Miron, Dalia Simona ^a,c   Niţulescu, George Mihai ^a,c   Ciolan, Dragoş ^a,c   Majekova, Magdalena ^b,c  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

^b INSTITUTE OF EXPERIMENTAL PHARMACOLOGY AND TOXICOLOGY   (Slovakia)

^c CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Biopharmaceutics; Dibenzothiepines; Logs (BB= the brain blood concentration ratio); Molecular descriptors

Indexed keywords

DIBENZOTHIEPIN DERIVATIVE; PSYCHOTROPIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; CORNEA; DRUG PENETRATION; DRUG STRUCTURE; DRUG TRANSFORMATION; EXPERIMENTAL DOG; EXPERIMENTAL RABBIT; HUMAN; HUMAN TISSUE; JEJUNUM; KIDNEY CELL; LIPOPHILICITY; MEMBRANE PERMEABILITY; MOLECULAR DYNAMICS; NONHUMAN; PERMEABILITY; PREDICTION; QUANTITATIVE ANALYSIS; SOLUBILITY; STRATUM CORNEUM;

EID: 83455199010     PISSN: 00148237     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Keller TH, Pichota A, Yin Z. A practical view of 'druggability'. Curr Opin Chem Biol. 2006;10:357-361.
2. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46:3-26.
3. Didziapetris R, Japertas P, Avdeef A, Petrauskas A. Classification analysis of P-glycoprotein substrate specificity. J Drug Target. 2003;11:391-406.
4. Mircioiu C., Ionicǎ G., Danilceac A., Miron DS, Mircioiu I, Rǎdulescu FS, Pharmacokinetic and mathematical outliers for drugs with active metabolites. Note I. Model Independent analyses for pentoxifylline, Farmacia, 2010, 58, 3, 264-278
5. Van de Waterbeemd H, Smith DA, Jones BC. Lipophilicity in pk design: Methyl, ethyl, futile. J Comput Aided Mol Des. 2001;15:273-286
6. Mircioiu C., Mircioiu I, Voicu V., Miron D., Dissolution- bioequivalence non- correlations, Basic & Clinical Pharmacology & Toxicology, 2005, 96, 3, 262-264
7. Voicu VA, de Leon J, Medvedovici AV, Radulescu FS, Miron DS. New insights on the consequences of biotransformation processes on the distribution and pharmacodynamic profiles of some neuropsychotropic drugs. Eur Neuropsychopharmacol. 2011, doi:10.1016/j.euroneuro. 2011.08.004
8. Voicu V, Thiermann H., Rǎdulescu FS, Miron D, The toxicokinetics and toxicodynamics of organophosphonates versus the pharmacokinetics and pharmacodynamics of oxime antidotes: biological consequences, Basic & Clinical Pharmacology & Toxicology, 2010, 106, 2, 73-85
9. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413-420
10. Amidon GE, Hawley M. Oral bioperformance and 21st century dissolution. Mol Pharm. 2010, doi: 10.1021/mp100275b
11. Benet LZ, Amidon GL, Barends DM, Lennernas H, Polli JE, Shah VP, Stavchansky SA, Yu LX. The use of BDDCS in classifying the permeability of marketed drugs. Pharm Res. 2008;25:483-488.
12. Van de Waterbeemd H. From in vivo to in vitro/in silico ADME: Progress and challenges. Expert Opin Drug Metab Toxicol. 2005;1:1-4.
13. Klein S. The use of biorelevant dissolution media to forecast the in vivo performance of a drug. AAPS J. 2010;12:397-406.
14. Jantratid E, De Maio V, Ronda E, Mattavelli V, Vertzoni M, Dressman JB. Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form. Eur J Pharm Sci. 2009;37:434-441.
15. Fagerholm U. The role of permeability in drug ADME/pk, interactions and toxicity--presentation of a permeability-based classification system (PCS) for prediction of ADME/pk in humans. Pharm Res. 2008;25:625-638.
16. Fagerholm U. ADMET Predictor™ (Simulations Plus, Inc., Lancaster, California, USA)
17. Chifiriuc M. C., Stecoza C.E., Lazar V., Dracea O., Larion C., Israil A. M., Antimicrobial activity of some new O-acyloximino-dibenzo[b,e]thiepins and O-acyloximino-dibenzo[b,e]thiepin-5,5-dioxides against planktonic cells, Romanian Biotechnological Letters, 2010, 15(2), 5134-5139
18. Stecoza C.E., Cǎproiu M.T., Drǎghici C., Chifiriuc M. C., Dracea N.O., Synthesis, characterization and antimicrobial activity evaluation of some new derivatives of 6,11-dihydrodibenzo[b,e]thiepin 5,5-dioxide, Revista de Chimie (Bucureşti) 2009, 60, 2, 137-141
19. Stecoza C.E., Chifiriuc M. C., Israil A. M., Screening of the antimicrobial activity of some new dibenzo[b,e]thiepine derivatives. Note 1, Farmacia, 2008, 56, 5, 491-500
20. Stecoza C.E., Cǎproiu M.T, Drǎghici C., Ilie C., New 6,11-dihydrodibenzo[b,e]thiepine derivatives. Note VI, Farmacia, 2009, 57, 5, 616-624
21. Tarko L., Stecoza C.E., Niţulescu G. M., Ilie C., Chifiriuc M. C., QSARs on antibacterial activity of some new, not yet synthesized, substituted dihydrodibenzothiepins, Rev. Chim. (Bucureşti), 2010, 61(3), 263-266
22. Tarko L., Stecoza C.E., Niţulescu G. M., Ilie C., Chifiriuc M. C PALLAS 3.1.1.2 (CompuDrug International Ltd., USA)
23. Farahmand S, Maibach HI. Estimating skin permeability from physicochemical characteristics of drugs: A comparison between conventional models and an in vivo based approach. Int J Pharm. 2009;375:41-47.